SMAD3 and osteoporosis: Therefore, psoralen may be a viable drug for the treatment of osteoporosis, and HUANG et al. found that psoralen promoted the differentiation of hBMSCs through the activation of the TGF-β/Smad3 pathway to accelerate osteogenesis, which may be of future value in the clinical treatment of osteoporosis [26].